Cognition Therapeutics In... (CGTX)
NASDAQ: CGTX
· Real-Time Price · USD
1.33
0.07 (5.56%)
At close: Sep 26, 2025, 3:59 PM
1.36
2.26%
After-hours: Sep 26, 2025, 07:57 PM EDT
5.56% (1D)
| Bid | 1.32 |
| Market Cap | 97.86M |
| Revenue (ttm) | 250K |
| Net Income (ttm) | -32.99M |
| EPS (ttm) | -0.66 |
| PE Ratio (ttm) | -2.02 |
| Forward PE | -4.82 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.35 |
| Volume | 1,491,104 |
| Avg. Volume (20D) | 11,378,977 |
| Open | 1.26 |
| Previous Close | 1.26 |
| Day's Range | 1.25 - 1.34 |
| 52-Week Range | 0.22 - 3.83 |
| Beta | 1.33 |
| Ex-Dividend Date | n/a |
About CGTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CGTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CGTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-18.95%
Cognition Therapeutics shares are trading lower af...
Unlock content with
Pro Subscription
1 month ago
+10.91%
Cognition Therapeutics shares are trading higher after the company announced FDA confirmation of its Phase 3 trial design for Alzheimer's drug Zervimesine.
